Which numbing drug works best for dialysis access surgery?
NCT ID NCT07259772
First seen Dec 08, 2025 · Last updated Jun 17, 2026 · Updated 33 times
Summary
This study tests two numbing medicines, ropivacaine and lidocaine, in 40 adults with end-stage kidney disease who need surgery to create a blood vessel connection (fistula) for dialysis. Patients are randomly assigned to receive one of the two drugs during surgery, and neither they nor their surgeons know which one is used. Researchers measure pain levels, surgery time, need for extra pain relief, and how well the fistula works over the next 5 years. The goal is to find which drug provides better pain control and may improve long-term surgical success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE (ESRD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lianyungang First People's Hospital
Lianyungang, Jiangsu, 222000, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.